Circulating tumor DNA (ctDNA) informs predictive biomarkers in non–small-cell lung cancer, but the presence of ctDNA itself could also be a prognostic indicator.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450 (accessed September 2022).
Lindeman, N. I. et al. J. Thorac. Oncol. 13, 323–358 (2018).
Planchard, D. et al. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 29, iv192–iv237 (2018).
Jee, J. et al. Nat. Med. https://doi.org/10.1038/s41591-022-02047-z (2022).
Paweletz, C. P., Lau, C. J. & Oxnard, G. R. JCO Precis. Oncol. 3, 1–3 (2019).
Gray, J. E. et al. Clin. Cancer Res. 25, 6644–6652 (2019).
Rolfo, C. et al. J. Thorac. Oncol. 16, 1647–1662 (2021).
Bettegowda, C. et al. Sci. Transl. Med. 6, 224ra24 (2014).
Serrano, C. et al. BMC Cancer 20, 1–12 (2020).
Schrag, D. et al. Ann. Oncol. 33, S417–S426 (2022).
Abbosh, C. et al. Nature 545, 446–451 (2017).
Kustanovich, A., Schwartz, R., Peretz, T. & Grinshpun, A. Cancer Biol. Ther. 20, 1057–1067 (2019).
Acknowledgements
We thank A. Wren and J. Carmona for editorial assistance. A.V. acknowledges the FERO Foundation for their funding support to the DIAMAV (Advanced Molecular Diagnostics) Program and the Cellex Foundation for providing research facilities and equipment.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.V. reports personal financial interest in the form of scientific consultancy roles for Bayer, Bristol-Myers Squibb, Guardant Health, Incyte, Merck Serono, Novartis and Roche. J.T. reports personal financial interest in the form of scientific consultancy roles for Array Biopharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, Inspirna Inc, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapeutics, Seattle Genetics, Servier, Sotio Biotech, Taiho, Tessa Therapeutics and TheraMyc, as well as stock holdings in Oniria Therapeutics and also educational collaboration with Imedex/HMP, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education and Physicians Education Resource (PER).
Rights and permissions
About this article
Cite this article
Vivancos, A., Tabernero, J. Circulating tumor DNA as a novel prognostic indicator. Nat Med 28, 2255–2256 (2022). https://doi.org/10.1038/s41591-022-02068-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-02068-8